Sugi Predict

Sugi Predict / Compounds / SCHEMBL149779

SCHEMBL149779

SCHEMBL149779

Nc1nonc1/C(=N\O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 9/20 0.61
▸ TDO2 P48775 2/20 0.61
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ FADS1 O60427 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19654569 1.00 IDO1 (0.61) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL30449075 1.00 IDO1 (0.61) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL19654573 1.00 IDO1 (0.61) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL29627125 1.00 IDO1 (0.61) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL149780 1.00 IDO1 (0.61) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL2520573 0.88 IDO1 (0.47) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL21118296 0.88 IDO1 (0.50) IDO1TDO2MAPTHTTLMNA
SCHEMBL21118334 0.88 IDO1 (0.47) IDO1TDO2MEN1KMT2AMAPT
SCHEMBL2516714 0.88 IDO1 (0.50) IDO1TDO2MAPTHTTLMNA
SCHEMBL2516716 0.88 IDO1 (0.50) IDO1TDO2MAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003536-A1 ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF Agenus Inc. (US) 2022-06-01 — — EP claimed
EP-4004031-A2 ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF Agenus Inc. (US) 2022-06-01 — — EP claimed
US-11065317-B2 Heat shock protein-binding peptide compositions and methods of use thereof AGENUS INC. (US) 2021-07-20 — — US claimed
WO-2021016531-A1 ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF AGENUS INC. (US) 2021-01-28 — — WO claimed
WO-2021016534-A2 ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF AGENUS INC. (US) 2021-01-28 — — WO claimed
EP-3294324-A1 VACCINES FOR TREATMENT AND PREVENTION OF CANCER Agenus Inc. (US) 2018-03-21 — — EP claimed
US-20160331821-A1 VACCINES FOR TREATMENT AND PREVENTION OF CANCER AGENUS INC. 2016-11-17 — — US claimed
WO-2016183486-A1 VACCINES FOR TREATMENT AND PREVENTION OF CANCER AGENUS INC. (US) 2016-11-17 — — WO claimed
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 — — EP claimed
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2014-12-25 — — US claimed
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2013-05-16 — — US claimed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 — — US claimed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 — — US claimed
US-12440451-B2 Compositions and methods using an epigenetic inhibitor DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-10-14 — — US disclosed
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE HOLDINGS CORPORATION 2024-05-30 — — US disclosed
EP-2911669-B1 SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER UNIV CHICAGO (US) 2024-04-10 — — EP disclosed
EP-1879573-A4 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORP (US) 2009-07-08 — — EP disclosed
EP-1879573-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-01-23 — — EP disclosed
WO-2006122150-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2006-11-16 — — WO disclosed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT IDO1 1/4885TDO2 5/4885MEN1 1453/4885
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885TDO2 6/4885MEN1 3670/4885
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885TDO2 6/4885MEN1 3670/4885
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885TDO2 6/4885MEN1 3670/4885
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885TDO2 6/4885MEN1 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.